Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Genzyme, a Sanofi Company | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that has returned or has not responded to prior treatment. The study will specifically investigate the impact of administering lower-than-standard doses of pomalidomide and dexamethasone. Using lower doses of pomalidomide and dexamethasone in this setting has not been approved by the Food and Drug Administration (FDA).
This study aims to address the challenges faced in selecting appropriate therapy for elderly or highly toxicity-vulnerable patients who are poor candidates for standard (full-dose) chemotherapy regimens. Traditional clinical trials often exclude these patients, limiting the generalizability of available data. This single-arm multicenter phase II study will enroll 49 older and/or toxicity-vulnerable patients with RRMM. The study will evaluate the safety and effectiveness of isatuximab when used in combination with pomalidomide and dexamethasone at lower than standard doses. The primary objective is to estimate the overall response rate (ORR), while secondary objectives include the estimation of additional measures of response, as well as measures of toxicity and tolerability. All participants in the trial will also be evaluated by Cancer and Aging Research Group Geriatric Assessments (CARG-GA) and patient- reported outcome (PRO) measures of quality of life (QOL). Biomarkers of aging and frailty will also be studied.
Duration of therapy:
The duration of study participation will depend on the response to the treatment. In the absence of treatment delays due to adverse events, treatment with Isa-Pd will generally continue until disease progression, unacceptable side effects, other illness or condition that prevents further study treatment, or a subject's decision to withdraw from the study. On average, subjects will most likely be treated for approximately 10 months on this study.
Duration of Follow-Up:
All participants, including those withdrawn for adverse events (AEs) will be followed after removal from study treatment until death or full subject withdrawal from the study for other reasons. Participants removed from the study treatment for unacceptable AEs will be followed for resolution or stabilization of the AEs.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Arm | Experimental | Subjects with relapsed or refractory multiple myeloma receiving the study treatment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Isatuximab | Drug | Pharmaceutical form: Solution for infusion. Route of administration: Intravenous 10 mg/kg will be administered intravenously once weekly during cycle 1 and every other week during each subsequent cycle. |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Response Rate (ORR) | Overall response rate (ORR) is defined as the percentage of participants achieving a partial response or better (≥PR) per IMWG criteria. The number and percentage of participants achieving at least a partial response were reported. Complete response (CR) requires negative serum and urine immunofixation, disappearance of plasmacytomas, and <5% bone marrow plasma cells; stringent complete response (sCR) requires CR plus a normal free light chain ratio and no clonal plasma cells in bone marrow. Very good partial response (VGPR) is defined as M-protein detectable by immunofixation but not electrophoresis, or a ≥90% reduction in serum M-protein with urine M-protein <100 mg/24h. Partial response (PR) is defined as a ≥50% reduction in serum M-protein and a ≥90% reduction in 24-hour urine M-protein (or to <200 mg/24h), with a ≥50% reduction in plasmacytomas if present at baseline. | Up to 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment Related Adverse Events Rate | All treatment-related adverse events as defined by changes from baseline utilizing National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0. NCI-CTCAE is a descriptive terminology utilized for AE reporting. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. |
Not provided
Inclusion Criteria:
A. Score ≥ 2 (indicating "frail") on the International Myeloma Working Group instrument (IMWG; Palumbo et al. [Blood 2015]) B.KPS ≤ 70
C. Not meeting criteria A or B above but felt by treating clinician to not be a candidate for a standard full-dose regimen on account of one of the following:
i) History of clinically significant non-hematologic grade ≥3 (NCI CTCAE, version 5.0) toxicity attributed to prior anticancer therapy ii) History of requiring dose-reduction of at least two separate anticancer drugs during prior therapy for multiple myeloma.
Exclusion Criteria:
All subjects meeting any of the listed exclusion criteria at baseline with be excluded from study participation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Eben I Lichtman, MD | UNC Lineberger Comprehensive Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27514 | United States | ||
| Atrium Health Wake Forest Baptist Medical Center |
Not provided
| Label | URL |
|---|---|
| University of North Carolina Lineberger Comprehensive Cancer Center Clinical Trials | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Six participants were enrolled at a single U.S. center between December 5, 2023, and March 20, 2025.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Experimental: Single Arm | Subjects with relapsed or refractory multiple myeloma receiving the study treatment. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Experimental: Single Arm | Subjects with relapsed or refractory multiple myeloma receiving the study treatment. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Overall Response Rate (ORR) | Overall response rate (ORR) is defined as the percentage of participants achieving a partial response or better (≥PR) per IMWG criteria. The number and percentage of participants achieving at least a partial response were reported. Complete response (CR) requires negative serum and urine immunofixation, disappearance of plasmacytomas, and <5% bone marrow plasma cells; stringent complete response (sCR) requires CR plus a normal free light chain ratio and no clonal plasma cells in bone marrow. Very good partial response (VGPR) is defined as M-protein detectable by immunofixation but not electrophoresis, or a ≥90% reduction in serum M-protein with urine M-protein <100 mg/24h. Partial response (PR) is defined as a ≥50% reduction in serum M-protein and a ≥90% reduction in 24-hour urine M-protein (or to <200 mg/24h), with a ≥50% reduction in plasmacytomas if present at baseline. | Participants received study treatment for up to 12 weeks, at which point tumor response was assessed. | Posted | Count of Participants | Participants | Up to 12 weeks |
|
Up to a maximum of 383 days (including 30 days after the last treatment). Protocol treatment duration is variable, and continues until disease progression, unacceptable toxicity, intercurrent illness, pregnancy, subject withdrawal, investigator decision, or loss to follow-up.
CTCAE version 5.0
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Experimental: Single Arm | Subjects with relapsed or refractory multiple myeloma receiving the study treatment. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | CTCAE v5 | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Melahat Canter | UNC Lineberger Comprehensive Cancer Center | (919) 962-0000 | Melahat_Canter@med.unc.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 2, 2024 | Apr 10, 2026 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| D012008 | Recurrence |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000599209 | isatuximab |
| C467566 | pomalidomide |
| D003907 | Dexamethasone |
| ID | Term |
|---|---|
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Pomalidomide | Drug | Pharmaceutical form: Pill for oral use. Route of administration: 3 mg Pomalidomide 3 mg pill will be taken by mouth once daily on days 1-21 of each 28-day cycle. |
|
| Dexamethasone | Drug | Pharmaceutical form: Tablet for oral use Route of administration: Pill for oral use. Dexamethasone 20 mg tablet will be taken by mouth once per week. |
|
| Up to 12 weeks |
| Treatment Failure-free Survival (TFFS) | TFFS is defined as the time start from the first day of study therapy until discontinuation for any reason, including disease progression, toxicity, or death. Progressive disease: Serum M-protein: absolute increase must be ≥ 0.5 g/dL, ≥ 1 g/dL if the lowest M component was ≥ 5 g/dL; absolute Urine M-protein increase≥ 200 mg/24 h). In patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels must be > 10 mg/dL; without measurable involved FLC levels, bone marrow plasma cell percentage irrespective of baseline status Appearance of a new lesion(s), ≥ 50% increase from nadir > 1 lesion, or ≥ 50% increase in the longest diameter of a previous lesion >1 cm in short axis;≥ 50% increase e in circulating plasma cells (minimum of 200 cells per μL) if this is the only measure of disease. | Up to 3 years |
| Maximum Depth of Response | Maximum depth of response includes the summation of minimal response (MR), partial response (PR), very good partial response (VGPR), complete response (CR), and stringent complete response (sCR) based on IMWG criteria. Minimal response(MR): ≥ 25% but ≤ 49% reduction of serum M-protein and reduction in 24-h urine M-protein by 50-89%, if present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required. PR, VGPR, CR, and sCR were defined above. | Up to 12 weeks |
| Clinical Benefit Rate (CBR) | CBR is defined as a partial response or better (≥PR) + minimal response (MR) rate based on International Myeloma Working Group (IMWG) criteria. | Up to 12 weeks |
| Bone Marrow Minimal Residual Disease (MRD) Negativity | Bone marrow minimal residual disease (MRD) negativity will be defined as the ratio of subjects who achieved MRD to all subjects. MRD negativity will be assessed by next-generation sequencing with a minimum sensitivity of 1x10-5. | Up to 12 weeks |
| Time to First Response | Time to first response is defined as the time from the first study treatment to the achievement of PR or better as defined by IMWG criteria. | Up to 12 weeks |
| Time to Best Response | Time to best response is defined as the time from the first study treatment to the achievement of best response (PR, VGPR, CR, or sCR) based on IMWG criteria. | Up to 12 weeks |
| Duration of Response | Duration of response is defined as the time from the achievement of PR or better until progressive disease (PD) based on IMWG criteria. Subjects will be censored if they die of anything other than myeloma. | Up to 3 years |
| Progression-free Survival (PFS) | PFS is defined as the time from the first study treatment until confirmed PD based on IMWG criteria or death from any cause, whichever comes first. | Up to 3 years |
| Median Time to Next Treatment (TTNT) | Median time to next treatment (TTNT) is defined as the time from the start of the study treatment to the next type of Multiple Myeloma treatment or death from any cause, whichever occurs first. | Up to 3 years |
| Overall Survival | Overall survival is defined as the time from the first study treatment to death from any cause. | Up to 3 years |
| Winston-Salem |
| North Carolina |
| 27157 |
| United States |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG000 | Experimental: Single Arm | Subjects with relapsed or refractory multiple myeloma receiving the study treatment. |
|
|
| Secondary | Treatment Related Adverse Events Rate | All treatment-related adverse events as defined by changes from baseline utilizing National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0. NCI-CTCAE is a descriptive terminology utilized for AE reporting. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. | Not Posted | Up to 12 weeks | Participants |
| Secondary | Treatment Failure-free Survival (TFFS) | TFFS is defined as the time start from the first day of study therapy until discontinuation for any reason, including disease progression, toxicity, or death. Progressive disease: Serum M-protein: absolute increase must be ≥ 0.5 g/dL, ≥ 1 g/dL if the lowest M component was ≥ 5 g/dL; absolute Urine M-protein increase≥ 200 mg/24 h). In patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels must be > 10 mg/dL; without measurable involved FLC levels, bone marrow plasma cell percentage irrespective of baseline status Appearance of a new lesion(s), ≥ 50% increase from nadir > 1 lesion, or ≥ 50% increase in the longest diameter of a previous lesion >1 cm in short axis;≥ 50% increase e in circulating plasma cells (minimum of 200 cells per μL) if this is the only measure of disease. | Not Posted | Up to 3 years | Participants |
| Secondary | Maximum Depth of Response | Maximum depth of response includes the summation of minimal response (MR), partial response (PR), very good partial response (VGPR), complete response (CR), and stringent complete response (sCR) based on IMWG criteria. Minimal response(MR): ≥ 25% but ≤ 49% reduction of serum M-protein and reduction in 24-h urine M-protein by 50-89%, if present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required. PR, VGPR, CR, and sCR were defined above. | Not Posted | Up to 12 weeks | Participants |
| Secondary | Clinical Benefit Rate (CBR) | CBR is defined as a partial response or better (≥PR) + minimal response (MR) rate based on International Myeloma Working Group (IMWG) criteria. | Not Posted | Up to 12 weeks | Participants |
| Secondary | Bone Marrow Minimal Residual Disease (MRD) Negativity | Bone marrow minimal residual disease (MRD) negativity will be defined as the ratio of subjects who achieved MRD to all subjects. MRD negativity will be assessed by next-generation sequencing with a minimum sensitivity of 1x10-5. | Not Posted | Up to 12 weeks | Participants |
| Secondary | Time to First Response | Time to first response is defined as the time from the first study treatment to the achievement of PR or better as defined by IMWG criteria. | Not Posted | Up to 12 weeks | Participants |
| Secondary | Time to Best Response | Time to best response is defined as the time from the first study treatment to the achievement of best response (PR, VGPR, CR, or sCR) based on IMWG criteria. | Not Posted | Up to 12 weeks | Participants |
| Secondary | Duration of Response | Duration of response is defined as the time from the achievement of PR or better until progressive disease (PD) based on IMWG criteria. Subjects will be censored if they die of anything other than myeloma. | Not Posted | Up to 3 years | Participants |
| Secondary | Progression-free Survival (PFS) | PFS is defined as the time from the first study treatment until confirmed PD based on IMWG criteria or death from any cause, whichever comes first. | Not Posted | Up to 3 years | Participants |
| Secondary | Median Time to Next Treatment (TTNT) | Median time to next treatment (TTNT) is defined as the time from the start of the study treatment to the next type of Multiple Myeloma treatment or death from any cause, whichever occurs first. | Not Posted | Up to 3 years | Participants |
| Secondary | Overall Survival | Overall survival is defined as the time from the first study treatment to death from any cause. | Not Posted | Up to 3 years | Participants |
| 0 |
| 6 |
| 0 |
| 6 |
| 6 |
| 6 |
| Watering eyes | Eye disorders | CTCAE v5 | Non-systematic Assessment |
|
| Bloating | Gastrointestinal disorders | CTCAE v5 | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | CTCAE v5 | Non-systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | CTCAE v5 | Non-systematic Assessment |
|
| Dry mouth | Gastrointestinal disorders | CTCAE v5 | Non-systematic Assessment |
|
| Gastrointestinal disorders - Other, specify | Gastrointestinal disorders | CTCAE v5 | Non-systematic Assessment |
|
| Edema limbs | General disorders | CTCAE v5 | Non-systematic Assessment |
|
| Fatigue | General disorders | CTCAE v5 | Non-systematic Assessment |
|
| Flu like symptoms | General disorders | CTCAE v5 | Non-systematic Assessment |
|
| Non-cardiac chest pain | General disorders | CTCAE v5 | Non-systematic Assessment |
|
| Allergic reaction | Immune system disorders | CTCAE v5 | Non-systematic Assessment |
|
| Infections and infestations - Other, specify | Infections and infestations | CTCAE v5 | Non-systematic Assessment |
|
| Upper respiratory infection | Infections and infestations | CTCAE v5 | Non-systematic Assessment |
|
| Infusion related reaction | Injury, poisoning and procedural complications | CTCAE v5 | Non-systematic Assessment |
|
| Aspartate aminotransferase increased | Investigations | CTCAE v5 | Non-systematic Assessment |
|
| Lymphocyte count decreased | Investigations | CTCAE v5 | Non-systematic Assessment |
|
| Neutrophil count decreased | Investigations | CTCAE v5 | Non-systematic Assessment |
|
| Platelet count decreased | Investigations | CTCAE v5 | Non-systematic Assessment |
|
| White blood cell decreased | Investigations | CTCAE v5 | Non-systematic Assessment |
|
| Hyperglycemia | Metabolism and nutrition disorders | CTCAE v5 | Non-systematic Assessment |
|
| Hypernatremia | Metabolism and nutrition disorders | CTCAE v5 | Non-systematic Assessment |
|
| Hypoalbuminemia | Investigations | CTCAE v5 | Non-systematic Assessment |
|
| Hypocalcemia | Investigations | CTCAE v5 | Non-systematic Assessment |
|
| Hypokalemia | Investigations | CTCAE v5 | Non-systematic Assessment |
|
| Hypophosphatemia | Investigations | CTCAE v5 | Non-systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | CTCAE v5 | Non-systematic Assessment |
|
| Muscle cramp | Musculoskeletal and connective tissue disorders | CTCAE v5 | Non-systematic Assessment |
|
| Musculoskeletal and connective tissue disorder - Other, specify | Musculoskeletal and connective tissue disorders | CTCAE v5 | Non-systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | CTCAE v5 | Non-systematic Assessment |
|
| Amnesia | Nervous system disorders | CTCAE v5 | Non-systematic Assessment |
|
| Dizziness | Nervous system disorders | CTCAE v5 | Non-systematic Assessment |
|
| Dysgeusia | Nervous system disorders | CTCAE v5 | Non-systematic Assessment |
|
| Headache | Nervous system disorders | CTCAE v5 | Non-systematic Assessment |
|
| Tremor | Nervous system disorders | CTCAE v5 | Non-systematic Assessment |
|
| Anxiety | Psychiatric disorders | CTCAE v5 | Non-systematic Assessment |
|
| Insomnia | Psychiatric disorders | CTCAE v5 | Non-systematic Assessment |
|
| Urinary urgency | Renal and urinary disorders | CTCAE v5 | Non-systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | CTCAE v5 | Non-systematic Assessment |
|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | CTCAE v5 | Non-systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | CTCAE v5 | Non-systematic Assessment |
|
| "Skin and subcutaneous tissue disorders - Other, specify" | Skin and subcutaneous tissue disorders | CTCAE v5 | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000072473 |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |